CHENGDA PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 16.7733 million yuan, a decrease of 58.47%
I'm PortAI, I can summarize articles.
CHENGDA PHARMA released its third-quarter report for 2025, with operating revenue of 285 million yuan in the first three quarters, a year-on-year increase of 16.95%. The net profit attributable to the parent company was 16.7733 million yuan, a year-on-year decrease of 58.47%; the net profit after deducting non-recurring gains and losses was 3.9025 million yuan, a year-on-year decrease of 72.96%. The basic earnings per share were 0.1107 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments